Digitale Bibliotheek
Sluiten Bladeren door artikelen uit een tijdschrift
 
Zoeken naar met titel:
ABCDEFGHIJKLMNOPQRSTUVWXYZ

     Tijdschrift beschrijving
       Alle jaargangen van het bijbehorende tijdschrift
         Alle afleveringen van het bijbehorende jaargang
                                       Alle artikelen van de bijbehorende aflevering
 
                             103 gevonden resultaten
nr titel auteur tijdschrift jaar jaarg. afl. pagina('s) type
1 OP1. Analysis and presentation of cost data from randomised trials Barber, J
 1997
 33 S9 p. S1-
1 p.
 artikel
2 OP27. Anastrozole 1 mg provides a cost-effective survival benefit, compared with megestrol acetate, for patients treated for advanced breast cancer Thompson, E
 1997
 33 S9 p. S11-
1 p.
 artikel
3 OP3. Applying time-dependent outcomes and Markov modelling to the economic evaluation of cytotoxics: A case study of paclitaxel and topotecan in the treatment of advanced ovarian cancer Bethel, LM
 1997
 33 S9 p. S1-S2
2 p.
 artikel
4 OP26. Assessing the relative costs of standard open surgery and laparoscopic surgery in colorectal cancer in a randomised controlled trial Stead, ML
 1997
 33 S9 p. S10-S11
2 p.
 artikel
5 OP25. A systematic review of health benefit valuation in economic evaluations in cancer Sculpher, M
 1997
 33 S9 p. S10-
1 p.
 artikel
6 OP2. Cost-effectiveness analysis of paclitaxel and cisplatinum versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer — A European perspective Berger, K
 1997
 33 S9 p. S1-
1 p.
 artikel
7 OP16. Cost-effectiveness and quality of life evaluation, in the context of current practice, of antiemetics used for the control of chemotherapy induced emesis Lachaine, J
 1997
 33 S9 p. S6-S7
2 p.
 artikel
8 OP30. Cost-effectiveness of faecal occult blood screening for colorectal cancer: results of the Nottingham trial Whynes, DK
 1997
 33 S9 p. S12-
1 p.
 artikel
9 OP4. Cost-effectiveness of Irinotecan (CPT-11) and best estimated chemotherapy regimen in patients with metastatic colorectal cancer after failure of 5fluorouracil (5FU) containing regimen: Results based on a phase III trial Blijham, G
 1997
 33 S9 p. S2-
1 p.
 artikel
10 OP24. Costs and quality of life in metastatic breast cancer Reboul-Marty, J
 1997
 33 S9 p. S9-S10
2 p.
 artikel
11 OP17. Costs and quality of life in metastatic colorectal cancer Launois, R
 1997
 33 S9 p. S7-
1 p.
 artikel
12 OP6. Costs of care in a randomised trial of early hospital discharge after surgery for breast cancer Bonnema, J
 1997
 33 S9 p. S2-S3
2 p.
 artikel
13 OP7. Country-specific adaptations of a cost-utility decision model comparing chemotherapy in recurrent metastatic breast cancer Brown, RE
 1997
 33 S9 p. S3-
1 p.
 artikel
14 OP33. Determining the importance of specific symptoms for the economic evaluation of advanced prostate cancer therapies Yabroff, KR
 1997
 33 S9 p. S13-
1 p.
 artikel
15 OP14. Diagnostic imaging in cancer. The economics of PET James, M
 1997
 33 S9 p. S5-S6
2 p.
 artikel
16 OP20. Discordance between physicians' estimations and breast cancer patients' self-assessment of side-effects of chemotherapy : An issue for measuring the impact of anticancer treatments Macquart-Moulin, G
 1997
 33 S9 p. S8-
1 p.
 artikel
17 OP5. Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone resistant prostate cancer based on a Canadian randomised trial with palliative endpoints Bloomfield, DJ
 1997
 33 S9 p. S2-
1 p.
 artikel
18 OP8. Economic implications of hepatic arterial infusion chemotherapy in the treatment of nonresectable colorectal liver metastases Durand-Zaleskski, I
 1997
 33 S9 p. S3-
1 p.
 artikel
19 OP13. Economics of the MRC colorectal working party CR06 trial Hale, J
 1997
 33 S9 p. S5-
1 p.
 artikel
20 OP22. Economie evaluation of Amifostine in the treatment of small cell lung cancer (SCLC) Poulter, KM
 1997
 33 S9 p. S9-
1 p.
 artikel
21 OP23. Elicitation of preferences and patients participation in the decision making process Protiere, C
 1997
 33 S9 p. S9-
1 p.
 artikel
22 OP28. Evaluation of economic consequences of general prostate cancer screening program in France: A decision model Thoral, F
 1997
 33 S9 p. S11-
1 p.
 artikel
23 OP11. Evaluation of relative costs of the cytostatic agents Tomudex® and 5-Fluorouracil plus Leucovorin as treatments for advanced colorectal cancer Groener, MGH
 1997
 33 S9 p. S4-S5
2 p.
 artikel
24 OP29. Institutional structure, financing mechanisms and heterogeneity in health care supply: Experience from 1078 breast cancer patients in a french region Tonnaire, G
 1997
 33 S9 p. S12-
1 p.
 artikel
25 OP10. Integrating patients' preferences in therapeutic decisions in cancer: Development of a decision board Ferdiaoui, N
 1997
 33 S9 p. S4-
1 p.
 artikel
26 OP21. Macro-financing mechanisms, micro-innovation incentives and resources (re-) allocation in anticancer treatments: experience from a French cancer institute Paraponaris, A
 1997
 33 S9 p. S8-S9
2 p.
 artikel
27 OP18. Optimization of peripheral blood stem cell collection (PBSC) by leukapheresis: a case of interaction between economic and clinical assessment of an innovation Le Corroller, AG
 1997
 33 S9 p. S7-
1 p.
 artikel
28 OP19. Quality of life assessments of patients with pancreatic cancer receiving MTA (LY231514, a multi-targeted antifolate) Liepa, AM
 1997
 33 S9 p. S8-
1 p.
 artikel
29 OP12. Results of an economic evaluation of a RCT of routine follow-up after primary treatment for breast cancer: A comparison of primary care vs specialist care Grunfeld, E
 1997
 33 S9 p. S5-
1 p.
 artikel
30 OP31. The cost of breast cancer: Implications for screening Wolstenholme, J
 1997
 33 S9 p. S12-S13
2 p.
 artikel
31 OP32. The cost of cervical cancer: Implications for screening Wolstenholme, J
 1997
 33 S9 p. S13-
1 p.
 artikel
32 OP9. The cost of radiotherapy at an Ontario regional cancer centre Earle, CU
 1997
 33 S9 p. S4-
1 p.
 artikel
33 OP15. Use of the EuroQoL among patients receiving radiochemotherapy for pancreatic cancer: Psychometrical tests and quality adjusted survival analysis König, HH
 1997
 33 S9 p. S6-
1 p.
 artikel
34 PP61. Adaptation of pharmacoecoitomic software Malfair Tavlor, SC
 1997
 33 S9 p. S37-
1 p.
 artikel
35 PP56. A model of patients' preferences for chemotherapy outcomes in advanced colorectal cancer: Do gains in survival justify the toxicity? Schmitt, C
 1997
 33 S9 p. S34-S35
2 p.
 artikel
36 PP23. An early economic evaluation of a therapeutic innovation in the field of cancerology: the case of the peripheral blood progenitor cells (PBPC) allogeneic transplantation Fortanier, C
 1997
 33 S9 p. S23-
1 p.
 artikel
37 PP17. An economic comparison of inpatient versus outpatient treatment of febrile neutropenia in a pediatric oncology ward Crott, R
 1997
 33 S9 p. S20-S21
2 p.
 artikel
38 PP53. A quality-adjusted survival (Q-TWIST) analysis of EORTC trial 30853 comparing maximal androgen blockade (MAB) with orchiectomy in patients with metastatic prostate cancer Rosendahl, KI
 1997
 33 S9 p. S33-S34
2 p.
 artikel
39 PP48. A review of the pharmacoeconomic research on Gemcitabine (GemzarTM) in the treatment of advanced non-small cell lung cancer Minshall, ME
 1997
 33 S9 p. S32-
1 p.
 artikel
40 PP55. Brain stem tumors treatment: Economical cost Sánchez de Toledo, J
 1997
 33 S9 p. S34-
1 p.
 artikel
41 PP26. Comparing the costs and cost-effectiveness of new chemotherapy regimens for treating non-small cell lung cancer (NSCLC) Gralla, RJ
 1997
 33 S9 p. S24-
1 p.
 artikel
42 PP13. Comparison of the cost of managing constipation in cancer patients receiving oral morphine or transdermal fentanyl Guest, J
 1997
 33 S9 p. S19-
1 p.
 artikel
43 PP3. Cost-analysis of cervical cancer screening in the Flemish Region: The spontaneous versus the organised approach Arbyn, M
 1997
 33 S9 p. S15-S16
2 p.
 artikel
44 PP60. Cost and outcome in UK palliative care services Small, N
 1997
 33 S9 p. S36-
1 p.
 artikel
45 PP28. Cost considerations in alternatives to inpatient care in the administration of chemotherapy and supportive care Grusenmeyer, PA
 1997
 33 S9 p. S24-S25
2 p.
 artikel
46 PP67. Cost effectiveness analysis of two strategies of treatment for stage III non surgical non small cell lung cancer 1997
 33 S9 p. S39-
1 p.
 artikel
47 PP62. Cost/effectiveness assessment of cytogenetic and molecular biology analysis for acute leukemia's prognosis Tonnaire, G
 1997
 33 S9 p. S37-
1 p.
 artikel
48 PP69. Cost effectiveness of FDG-PET in the evaluation of solitary pulmonary nodules Weber, W
 1997
 33 S9 p. S39-
1 p.
 artikel
49 PP4. Cost-effectiveness of radionuclide bone scanning to rule out asymptomatic bone metastases in clinically operable non-small cell lung cancer Arican, A
 1997
 33 S9 p. S16-
1 p.
 artikel
50 PP42. Cost-efficacy evaluation of fludarabine phosphate in the treatment of chronic lymhocytic leukemia refractory to other therapies Laplante, S
 1997
 33 S9 p. S29-S30
2 p.
 artikel
51 PP68. Cost identification of PAV versus ICE treatment in SCLC Rollier, P
 1997
 33 S9 p. S39-
1 p.
 artikel
52 PP27. Cost minimization analysis of treatment of T1N0 glottic squamous cell carcinomas: Comparison between radiotherapy, laser microsurgery and partial laryngectomy Grégoire, V
 1997
 33 S9 p. S24-
1 p.
 artikel
53 PP14. Cost of serious adverse drug reactions related to anti-cancer chemotherapy Couffignal, AL
 1997
 33 S9 p. S19-
1 p.
 artikel
54 PP44. Cost-quality of life study in advanced no metastatic breast cancer patients treated by a high dose chemotherapy with sequential reinfusion of blood stem cells Macquart-Moulin, G
 1997
 33 S9 p. S30-
1 p.
 artikel
55 PP9. Cost-quality of life study in inflammatory breast cancer (IBC) out patients receiving high dose intensity chemotherapy with RH-GCSF and stem cell support (PEGASE 2) Viens, P
 1997
 33 S9 p. S17-S18
2 p.
 artikel
56 PP2. Costs of inappropriate hospital use in cancer and non-cancer patients in a tertiary university hospital Akhan Ascioglu, S
 1997
 33 S9 p. S15-
1 p.
 artikel
57 PP12. Decision model for the cost of using opioids to treat cancer pain Guest, J
 1997
 33 S9 p. S18-S19
2 p.
 artikel
58 PP52. Determinants of treatment costs for stage III and IV colon cancer patients in Latvia. Evaluation of oral treatment with Ftorafur and Ftorafur/Leucovorin Plate, S
 1997
 33 S9 p. S33-
1 p.
 artikel
59 PP45. Development of a pharmacoeconomics service in a provincial oncology centre Malfair Tavlor, SC
 1997
 33 S9 p. S31-
1 p.
 artikel
60 PP34. Economic analysis of adjuvant interferon-ALFA 2B (IFN) in high risk melanoma using projections from ECOG (E) 1684 Hillner, BE
 1997
 33 S9 p. S27-
1 p.
 artikel
61 PP40. Economic Analysis of cancer treatments taking QoL into consideration Koinuma, N
 1997
 33 S9 p. S29-
1 p.
 artikel
62 PP41. Economic analysis of patients with breast cancer in a health maintenance organization Konski, A
 1997
 33 S9 p. S29-
1 p.
 artikel
63 PP30. Economic assessment of clodronate in the preventive treatment of bone resorption in patients with metastatic breast cancer Guignard, E
 1997
 33 S9 p. S25-
1 p.
 artikel
64 PP57. Economic burden of colon cancer in the US using a national database Seifeldin, R
 1997
 33 S9 p. S35-
1 p.
 artikel
65 PP36. economic effect of multiple fraction per day with acceleration (MF) in extended radiotherapy of patients with Hodgkin's disease (HD) Ilyin, NV
 1997
 33 S9 p. S27-
1 p.
 artikel
66 PP10. Economic evaluation of adjuvant treatment for early breast cancer Brown, J
 1997
 33 S9 p. S18-
1 p.
 artikel
67 PP50. Economic evaluation of endocrine therapies for post-menopausal metastatic breast cancer Sorensen, S
 1997
 33 S9 p. S32-S33
2 p.
 artikel
68 PP65. Economic evaluation of high dose chemotherapy for breast cancer patients van Enckevort, PJ
 1997
 33 S9 p. S38-
1 p.
 artikel
69 PP7. Economic evaluation of patients (pts) with lymphomas enrolled into phase II–III clinical trials (ct) in an oncology centre Bordonaro, R
 1997
 33 S9 p. S17-
1 p.
 artikel
70 PP29. Economic evaluation of the use of prophylactic clodronate to treat multiple myeloma Brace, NJ
 1997
 33 S9 p. S25-
1 p.
 artikel
71 PP54. Economic impact of the harmonization of practice using guidelines: The example of breast cancer surveillance Roy, T
 1997
 33 S9 p. S34-
1 p.
 artikel
72 PP46. Economies of scale and technological efficiency in state-wide cancer detection programs Mansley, EC
 1997
 33 S9 p. S31-
1 p.
 artikel
73 PP47. Efficiency of follow-up strategies after radical surgery for colonic cancer (RSCC). A decision analysis Michel, P
 1997
 33 S9 p. S31-S32
2 p.
 artikel
74 PP18. Hospital costs of intensive chemotherapy followed by peripheral stem cell reinfusion Donnet-Descartes, V
 1997
 33 S9 p. S21-
1 p.
 artikel
75 PP51. Information asymmetries and strategic consequences of a prospective payment-like regulation in health care: Evidence from the twenty French cancer institutes Paraponaris, A
 1997
 33 S9 p. S33-
1 p.
 artikel
76 PP38. Issues in developing an economic evaluation of an innovative cancer control program for the medically underserved Jones, WJ
 1997
 33 S9 p. S28-
1 p.
 artikel
77 PP49. Management of lung cancer — a comparison of management strategies, outcomes and resource utilisation in specialist and non specialist centres Stroner, PL
 1997
 33 S9 p. S32-
1 p.
 artikel
78 PP59. Medico-economic evaluation of breast cancer adjuvant treatment Bercez, C
 1997
 33 S9 p. S36-
1 p.
 artikel
79 PP58. Medico-economic evaluation of colorectal cancer screening programs: The Nord/Pas-de-Calais/Picardie experience Selke, B
 1997
 33 S9 p. S35-S36
2 p.
 artikel
80 PP6. Medico-economic evaluation of the cost of education in a cancer center Bercez, C
 1997
 33 S9 p. S16-S17
2 p.
 artikel
81 PP15. Methods for conducting economic analysis of the long-term management of breast cancer: Description of two current Canadian studies Coyle, D
 1997
 33 S9 p. S19-S20
2 p.
 artikel
82 PP16. Multi-centre economic evaluation of chart in the treatment of patients with head and neck cancer and carcinoma of the bronchus: Lessons for future studies Coyle, D
 1997
 33 S9 p. S20-
1 p.
 artikel
83 PP20. Opportunities to reduce the cost of care for breast cancer (BC) in Canada Evans, WK
 1997
 33 S9 p. S21-S22
2 p.
 artikel
84 PP37. Pharmacoeconomic analysis of the antagonists 5-HT3 in the control of chemotherapy-induced emesis in children Jiménez Monteagudo, M
 1997
 33 S9 p. S28-
1 p.
 artikel
85 PP19. Pharmacoeconomic evaluation of Etoposide Phosphate vs. Etoposide in small cell lung cancer: A European (five-country) study Doyle, JJ
 1997
 33 S9 p. S21-
1 p.
 artikel
86 PP21. President Reagan's colon cancer legacy: The long term public health and economic benefits of a discrete event Fabricant, RA
 1997
 33 S9 p. S22-
1 p.
 artikel
87 PP43. Quality of life assessments of patients with non-small cell lung cancer receiving gemcitabine (Gemzar™) and cisplatin Anton, A
 1997
 33 S9 p. S30-
1 p.
 artikel
88 PP1. Resource implications of paclitaxel/cisplatinum versus cyclophosphamide/cisplatinum in the treatment of advanced ovarian cancer. Adriaenssen, I
 1997
 33 S9 p. S15-
1 p.
 artikel
89 PP25. Resource use in the management of patients with Dukes' C colon carcinoma Glendenning, A
 1997
 33 S9 p. S23-S24
2 p.
 artikel
90 PP64. Resource utilisation in intensive chemotherapy, autologous versus allogeneic bone marrow transplantation in acute myeloid leukemia 1997
 33 S9 p. S37-S38
2 p.
 artikel
91 PP22. Revealed preferences in clinical trials Felder, S
 1997
 33 S9 p. S22-
1 p.
 artikel
92 PP63. Statistical inference and sample sizes for cost-effectiveness analyses van den Hout, W
 1997
 33 S9 p. S37-
1 p.
 artikel
93 PP11. Summary recommendations from the conference on purchasing oncology services: Methods & models in the marketplace Cangialose, CB
 1997
 33 S9 p. S18-
1 p.
 artikel
94 PP5. Teicoplanin or vancomycin in febrile neutropenic children with cancer: A randomized cost effectiveness study Aupérin, A
 1997
 33 S9 p. S16-
1 p.
 artikel
95 PP33. The benefit of stabilization under chemotherapy in metastatic colorectal cancer patients: A French prospective study Henry-Launois, B
 1997
 33 S9 p. S26-S27
2 p.
 artikel
96 PP39. The cost of radiation treatment at two Greek radiotherapy centres Kardamakis, D
 1997
 33 S9 p. S28-S29
2 p.
 artikel
97 PP24. The cost of the radiotherapy (RT): a Piedmont regional experience Gabriele, P
 1997
 33 S9 p. S23-
1 p.
 artikel
98 PP70. The costs of pancreatic cancer: Methodology of costing rare cancers Wilson, L
 1997
 33 S9 p. S40-
1 p.
 artikel
99 PP32. The impact of cancer on premature death in Japan Hamashima, C
 1997
 33 S9 p. S26-
1 p.
 artikel
100 PP8. The impact of changing the reimbursement system for radiotherapy in Catalonia Borràs, JM
 1997
 33 S9 p. S17-
1 p.
 artikel
101 PP31. The relative economics of screening for colorectal cancer, breast cancer and cervical cancer Gvrd-Hansen, D
 1997
 33 S9 p. S25-S26
2 p.
 artikel
102 PP35. Use of economic models in an evolving drug evaluation strategy: An example in treatment of metastatic breast cancer Hutton, J
 1997
 33 S9 p. S27-
1 p.
 artikel
103 PP66. Using appropriate comparators in economic evaluations: An exercise for Belgium Van Tigggelen, O
 1997
 33 S9 p. S38-
1 p.
 artikel
                             103 gevonden resultaten
 
 Koninklijke Bibliotheek - Nationale Bibliotheek van Nederland